{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:33Z","timestamp":1776408693608,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06870-z","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:52:39Z","timestamp":1772772759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of outcomes in autologous stem cell transplantation for hodgkin lymphoma over 2 decades at King Hussein cancer center"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2959-1177","authenticated-orcid":false,"given":"Zaid","family":"Abdel Rahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Alkhdour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Ribie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albatol","family":"Alamoush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fareed","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Alrawashdeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Abu Fara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Halahleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Al-Ibraheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ma\u2019koseh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"6","key":"6870_CR1","doi-asserted-by":"publisher","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","volume":"73","author":"VT Devita","year":"1970","unstructured":"Devita VT, Serpick AA, Carbone PP (1970) Combination chemotherapy in the treatment of advanced hodgkin\u2019s disease. Ann Intern Med 73(6):881\u2013895","journal-title":"Ann Intern Med"},{"issue":"1","key":"6870_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","volume":"36","author":"G Bonadonna","year":"1975","unstructured":"Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975) Combination chemotherapy of Hodgkin\u2019s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36(1):252\u20139","journal-title":"Cancer"},{"issue":"5","key":"6870_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1111961","volume":"366","author":"RM Meyer","year":"2012","unstructured":"Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN et al (2012) ABVD alone versus Radiation-Based therapy in Limited-Stage hodgkin\u2019s lymphoma. N Engl J Med 366(5):399\u2013408","journal-title":"N Engl J Med"},{"key":"6870_CR4","doi-asserted-by":"crossref","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al (2012 June) Results of a pivotal phase II study of Brentuximab Vedotin for patients with relapsed or refractory hodgkin\u2019s lymphoma. J Clin Oncol 20(18):2183\u20132189","DOI":"10.1200\/JCO.2011.38.0410"},{"issue":"4","key":"6870_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A et al (2018) Brentuximab Vedotin with chemotherapy for stage III or IV hodgkin\u2019s lymphoma. N Engl J Med 378(4):331\u2013344","journal-title":"N Engl J Med"},{"issue":"4","key":"6870_CR6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","volume":"28","author":"SM Ansell","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM, D\u0142ugosz-Danecka M, Kim WS, Gallamini A et al (2022) Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma. N Engl J Med 28(4):310\u2013320","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"6870_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2020-138546","volume":"136","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Boumendil A, Finel H, Khvedelidze I, Romejko-Jarosinska J, Tanase AD et al (2020) Evolution of outcome over time for relapsed hodgkin lymphoma after autologous stem cell transplant: improved survival for early relapse in recent years. Blood 136(Supplement 1):9\u201310","journal-title":"Blood"},{"issue":"12","key":"6870_CR8","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/ajh.27470","volume":"99","author":"SM Ansell","year":"2024","unstructured":"Ansell SM (2024) Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol 99(12):2367\u20132378","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"6870_CR9","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2022-162780","volume":"140","author":"S Luminari","year":"2022","unstructured":"Luminari S, Foss\u00e5 A, Trotman J, Molin D, d\u2019Amore FA, Enblad G et al (2022) Long Follow-up of the Response-Adjusted therapy for advanced hodgkin lymphoma (RATHL) trial (CRUK\/07\/033) confirms the safety of both De-Escalation and intensification of chemotherapy. Blood 140(Supplement 1):766\u2013767","journal-title":"Blood"},{"issue":"5","key":"6870_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.hoc.2007.07.008","volume":"21","author":"A Sureda","year":"2007","unstructured":"Sureda A (2007) Autologous and allogeneic stem cell transplantation in hodgkin\u2019s lymphoma. Hematol Oncol Clin North Am 21(5):943\u2013960","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9323","key":"6870_CR11","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet 359(9323):2065\u201371","journal-title":"Lancet"},{"issue":"3","key":"6870_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11899-014-0220-7","volume":"9","author":"F Montanari","year":"2014","unstructured":"Montanari F, Diefenbach C (2014) Relapsed Hodgkin lymphoma: management strategies. Curr Hematol Malig Rep 9(3):284\u201393","journal-title":"Curr Hematol Malig Rep"},{"issue":"8852","key":"6870_CR13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Goldstone AH, McMillan A, Chopra R, Vaughan Hudson G, Winfield D et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet 341(8852):1051\u20134","journal-title":"Lancet"},{"key":"6870_CR14","unstructured":"Jordan Cancer Registry Cancer Incidence in Jordan (2018) Available from: https:\/\/moh.gov.jo\/ebv4.0\/root_storage\/ar\/eb_list_page\/%D8%A7%D9%84%D8%AA%D9%82%D8%B1%D9%8A%D8%B1_%D8%A7%D9%84%D8%B3%D9%86%D9%88%D9%8A_%D9%84%D8%A7%D8%B5%D8%A7%D8%A8%D8%A7%D8%AA_%D8%A7%D9%84%D8%B3%D8%B1%D8%B7%D8%A7%D9%86_%D8%A7%D9%84%D9%85%D8%B3%D8%AC%D9%84%D8%A9_%D9%81%D9%8A_%D8%A7%D9%84%D8%A7%D8%B1%D8%AF%D9%86_%D9%84%D8%B9%D8%A7%D9%85_2018.pdf"},{"issue":"4","key":"6870_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.hemonc.2020.10.002","volume":"14","author":"TN Aladily","year":"2021","unstructured":"Aladily TN, Khreisat W, Ashukhaibi O, Alkhatib SM, Annab H, Tarawneh MS et al (2021) The epidemiology of lymphoma in jordan: A nationwide population study of 4189 cases according to world health organization classification system. Hematol Oncol Stem Cell Ther 14(4):336\u2013342","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"6870_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5402\/2012\/249124","volume":"2012","author":"F Abdel-Rahman","year":"2012","unstructured":"Abdel-Rahman F, Hussein A, Aljamily M, Al-Zaben A, Hussein N, Addasi A (2012) High-Dose therapy and autologous hematopoietic progenitor cells transplantation for recurrent or refractory hodgkin\u2019s lymphoma: analysis of King Hussein cancer center results and prognostic variables. ISRN Oncol 2012:1\u20135","journal-title":"ISRN Oncol"},{"key":"6870_CR17","doi-asserted-by":"crossref","unstructured":"Khalid H, Laith D, Mohamad M, Tahani S, Rawad R, Mohammad M et al (2018 ) High-dose therapy and autologous hematopoietic progenitor cells transplantation for relapsed or refractory hodgkin lymphoma: a follow up analysis of king hussein cancer center,results and prognostic variables. Trends Transplant [Internet]. [cited 2024 Apr 14];11(1). Available from: https:\/\/www.oatext.com\/high-dose-therapy-and-autologous-hematopoietic-progenitor-cells-transplantation-for-relapsed-or-refractory-hodgkin-lymphoma.php","DOI":"10.15761\/TiT.1000247"},{"issue":"11","key":"6870_CR18","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin\u2019s disease staging classification. Cancer Res 31(11):1860\u20131861","journal-title":"Cancer Res"},{"key":"6870_CR19","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al Recommendations for initial Evaluation, Staging, and response assessment of hodgkin and Non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014 Sept 20;32(27):3059\u20133067","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"6870_CR20","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2147\/DDDT.S136988","volume":"11","author":"RL Van Heertum","year":"2017","unstructured":"Van Heertum RL, Scarimbolo R, Wolodzko JG, Klencke B, Messmann R, Tunc F et al (2017) Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials. Drug Des Devel Ther 11:1719\u20131728","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"6870_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","volume":"95","author":"HJA Adams","year":"2016","unstructured":"Adams HJA, Kwee TC (2016) Prognostic value of pretransplant FDG-PET in refractory\/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Ann Hematol 95(5):695\u2013706","journal-title":"Ann Hematol"},{"issue":"8","key":"6870_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3109\/08880018.2015.1085934","volume":"32","author":"HJA Adams","year":"2015","unstructured":"Adams HJA, Nievelstein RAJ, Kwee TC (2015) Outcome of Hodgkin lymphoma patients with a posttreatment 18F-Fluoro-2-Deoxy-d-Glucose positron emission tomography (FDG-PET)-negative residual mass: systematic review and meta-analysis. Pediatr Hematol Oncol 32(8):515\u2013524","journal-title":"Pediatr Hematol Oncol"},{"issue":"23","key":"6870_CR23","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","volume":"116","author":"AJ Moskowitz","year":"2010","unstructured":"Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD et al (2010) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory hodgkin lymphoma. Blood 116(23):4934\u20134937","journal-title":"Blood"},{"issue":"9","key":"6870_CR24","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/bmt.2017.143","volume":"52","author":"M Damlaj","year":"2017","unstructured":"Damlaj M, Ghazi S, Syed G, Pasha T, Gmati G, Salama H et al (2017) Pre-autologous transplantation PET\/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplant 52(9):1342\u20134","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"6870_CR25","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.3390\/cancers17193242","volume":"17","author":"N Pugliese","year":"2025","unstructured":"Pugliese N, Picardi M, Vincenzi A, Giordano C, Lucania A, Severino A et al (2025) Routine imaging surveillance after frontline ABVD improves outcome in High-Risk hodgkin lymphoma. Cancers 17(19):3242","journal-title":"Cancers"},{"issue":"1","key":"6870_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1148\/radiol.14132154","volume":"272","author":"M Picardi","year":"2014","unstructured":"Picardi M, Pugliese N, Cirillo M, Zeppa P, Cozzolino I, Ciancia G et al (2014) Advanced-stage Hodgkin lymphoma: US\/chest radiography for detection of relapse in patients in first complete remission\u2013a randomized trial of routine surveillance imaging procedures. Radiology 272(1):262\u201374","journal-title":"Radiology"},{"issue":"9","key":"6870_CR27","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/bloodadvances.2019000123","volume":"3","author":"M Picardi","year":"2019","unstructured":"Picardi M, Della Pepa R, Giordano C, Pugliese N, Mortaruolo C, Trastulli F et al (2019) Brentuximab Vedotin followed by Bendamustine supercharge for refractory or relapsed hodgkin lymphoma. Blood Adv 3(9):1546\u20131552","journal-title":"Blood Adv"},{"issue":"5","key":"6870_CR28","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1111\/bjh.20053","volume":"206","author":"C Giordano","year":"2025","unstructured":"Giordano C, Picardi M, Pugliese N, Vincenzi A, Avilia S, De Fazio L et al (2025) Bendamustine supercharge plus Brentuximab Vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic hodgkin lymphoma in patients aged\u2009\u2264\u200960 years: Long-term efficacy results of a retrospective multicentre study. Br J Haematol 206(5):1502\u20131507","journal-title":"Br J Haematol"},{"issue":"31","key":"6870_CR29","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT et al (2014) Randomized comparison of Gemcitabine, Dexamethasone, and cisplatin versus Dexamethasone, Cytarabine, and cisplatin chemotherapy before autologous Stem-Cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 32(31):3490\u20133496","journal-title":"J Clin Oncol"},{"issue":"2","key":"6870_CR30","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1080\/10428194.2016.1193852","volume":"58","author":"AA Moccia","year":"2017","unstructured":"Moccia AA, Hitz F, Hoskins P, Klasa R, Power MM, Savage KJ et al (2017) Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed\/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leuk Lymphoma 58(2):324\u201332","journal-title":"Leuk Lymphoma"},{"key":"6870_CR31","doi-asserted-by":"crossref","unstructured":"Spinner MA, Sica RA, Tamaresis JS, Lu Y, Chang C, Lowsky R et al (2023) Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. ;blood.2022018827","DOI":"10.1182\/blood.2022018827"},{"issue":"3","key":"6870_CR32","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41375-021-01442-8","volume":"36","author":"PJ Br\u00f6ckelmann","year":"2022","unstructured":"Br\u00f6ckelmann PJ, M\u00fcller H, Gillessen S, Yang X, Koeppel L, Pilz V et al (2022) Clinical outcomes of relapsed and refractory hodgkin lymphoma patients after contemporary first-line treatment: a German hodgkin study group analysis. Leukemia 36(3):772\u2013780","journal-title":"Leukemia"},{"issue":"1","key":"6870_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.transproceed.2022.12.001","volume":"55","author":"B Deveci","year":"2023","unstructured":"Deveci B, Ate\u015fo\u011flu EB, Bayrak E, Kublashvili G, Topta\u015f T, Saba R et al (2023) Comparative efficacy and safety of BEAM and TEAM conditioning regimens for autologous stem cell transplantation in lymphoma patients. Transplant Proc 55(1):235\u201341","journal-title":"Transplant Proc"},{"key":"6870_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/09636897231179364","volume":"32","author":"R Wu","year":"2023","unstructured":"Wu R, Ma L (2023) BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as conditioning regimen before autologous haematopoietic cell transplantation: a systematic review and meta-analysis. Cell Transplant 32:9636897231179364","journal-title":"Cell Transplant"},{"key":"6870_CR35","doi-asserted-by":"crossref","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P et al (2017) Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 35(19):2125\u201332","DOI":"10.1200\/JCO.2016.72.1316"},{"issue":"14","key":"6870_CR36","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P et al (2019) Pembrolizumab in relapsed or refractory hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 134(14):1144\u20131153","journal-title":"Blood"},{"key":"6870_CR37","doi-asserted-by":"crossref","unstructured":"Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P et al (2018) Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from Lysa centers. Am J Hematol. June 8","DOI":"10.1002\/ajh.25154"},{"issue":"4","key":"6870_CR38","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/10428194.2021.2002322","volume":"63","author":"H Shah","year":"2022","unstructured":"Shah H, Jang H, Singh P, Kosti J, Kin A, Alavi A et al (2022) Improved post-ASCT survival of relapsed\/refractory classical hodgkin lymphoma patients in the era of novel agents. Leuk Lymphoma 63(4):813\u2013820","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06870-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:26Z","timestamp":1776405566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06870-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6870"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06870-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}